June 5, 2017 7:29am

 

I ask the same question all the time …  just don’t always expect the answer some want

It’s a question of when to buy or sell an investment, there are always risks …

 

Pre-open indication: five (5), 5 BUYS and 0 SELLS

 

Lower open expected

 

Critical information ahead of “our” universe’s open! I provide intelligence and analysis for short and near-term investment.

 

Are you reading; if not – you’re missing the facts in evidence that reflect reality and veracity? 

 

 

 

I know what a company is supposed to look like, be like, and smell like to succeed!

 

 

Dow futures are DOWN -0.10% and NASDAQ futures are DOWN -0.13%

 

U.S. stock index futures were expected to open little changed on Monday morning as traders paused for breath after various benchmark indexes hit record highs in the previous session.

European markets were mixed as investors digested fresh data and eyed an upcoming monetary policy meeting from the European Central Bank (ECB).

Asia closed mostly lower following an attack in central London over the weekend and as oil prices gained sharply after four countries snapped diplomatic ties with Qatar.

 

Data docket:  services PMI data for May released at around 9:45 a.m. ET, while ISM non-manufacturing data for May and factory orders for April are both scheduled for 10:00 a.m. ET.

 

 

The cell therapy sector closed POSITIVE on Friday and Thursday, NEGATIVE on Wednesday and Tuesday as lastMonday was a holiday.

The cell therapy sector’s record after the last 5 days (of 43 covered companies):

·         Friday closed POSITIVE with 11 decliners, 31 advancers and 1 flat;

·         Thursday closed POSITIVE with 10 decliners, 29 advancers and 4 flats;

·         Wednesday closed NEGATIVE with 24 decliners, 14 advancers and 5 flats;

·         Tuesday closed NEGATIVE with 29 decliners, 10 advancers and 4 flat;

·         Last Monday was Memorial Day and the U.S. markets were closed;

 

 

Remembering Friday’s closing bell newsletter, “a two day recovery … Momentum rehabilitates a relative strength drug and a sentiment therapy regenerates the sector as  the oversold pricing healing was quite remarkable.”

Reiterating, “Buying stocks that are oversold stimulated this share pricing recovery—a foundation of trading —has worked this year, so far, but may no longer be a sound strategy due to shifts in how sector operates.”

 

There is alwaays a gun <with trial result bullets> pointed at the head of the sector while risk is part and partnered with the sector!

​"Our" universe is or should be bracing ... for bright lights focused on the sector during the summer doldrums while politics could divert attention from the market "plays"!

​

We are also headed to the end of Q2 ... my comfort level is NERVOUS as to cash and cisbility issues on top of pricing sustainability ...!!

 

 

 

What did I see on Friday, the DOW closed UP +0.58% (+121.98) as the NASDAQ also closed UP +0.78% (+48.31) … while the CBOE Volatility Index (VIX) traded below 10 …

As I stated yesterday, companies are flocking to the  ASCO meeting … as investors wait to hear the progress.

The count:

•   Friday’s gainers ranged from +0.46% <VSTM> to +6.98% <JUNO> in 31 equities;

•   Friday’s decliners ranged from -0.33% <ONCE> to -3.85% <ISCO> in 11 equities;

​

I believe there will be limiting options on Monday ...

 

 

You’ve made it to the office, turned on the monitor, having just gotten your coffee and it hits you - what could be today’s trades? 

Watch list:

  • The iShares Nasdaq Biotechnology (IBB) closed up +1.68% on Frisday, and is NOT indicating ain Monday’s pre-market;
  • The SPDR S&P Biotech ETF (XBI) closed Friday up +2.18% and is NOT indicating in Monday pre-market;
  • The Health Care Select Sector SPDR ETF (XLV) closed up +0.65% Friday, and is indicating a negative -0.09%in Monday’s pre-open;
  • The iShares Russell 2000 (IWM) closed up +0.65% on Friday, and is indicating a POSITIVE +0.09% in Monday’s pre-open

 

 

Companies in my headlights:

Bellicum Pharmaceutics (BLCM) closed up +$0.06 to $10.99. The aftermarket indication was a positive +$0.20 or +1.82% - BUY;

bluebird bio (BLUE) closed up +$4.95 to $85.15. The aftermarket indication was +$0.05 or +0.06% - BUY;

Juno Therapeutics (JUNO) closed up +$1.71 t0 $26.21. The aftermarket indication is a positive +$0.06 or +3.21%. One reason, the initial – ASCO - BUY;

Kite Therapeutics (KITE) closed up +$0.83 to $75.49. The aftermarket indication is a positive +$0.84 or +0.65% - BUY;

Sangamo Therapeutics (SGMO) close up +$0.20 to $7.20. The aftermarket indication was a positive +$0.05 or +0.70% - BUY;

 

 

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Henry’s comments are for informational purposes only and are not a substitute for personalized advice. Consult your advisor about what is best for you.